Publication | Closed Access

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines

Hematological MalignancyCytocidal EffectP-glycoprotein-expressing SublinesMedicineHematologyImmunologyAnti-cancer AgentImmunotherapyOncologyRadiation OncologyAnti-cd33 Monoclonal AntibodyTumor BiologyHealth Sciences